User profiles for Jordi Antón

Jordi Antón

Sant Joan de Déu Hospital Barcelona, Universitat de Barcelona
Verified email at ub.edu
Cited by 9982

[HTML][HTML] Documento español de consenso sobre diagnóstico, estabilización y tratamiento del síndrome inflamatorio multisistémico pediátrico vinculado a SARS-CoV …

A García-Salido, J Antón, JD Martínez-Pajares… - Anales de …, 2021 - Elsevier
Se ha descrito un nuevo síndrome inflamatorio multisistémico pediátrico vinculado a SARS-CoV-2.
Este cuadro presenta una expresividad clínica variable y se asocia a infección activa …

Pyogenic bacterial infections in humans with MyD88 deficiency

…, E Ruiz-Ortiz, M Juan, C Fortuny, J Yagüe, J Antón… - Science, 2008 - science.org
MyD88 is a key downstream adapter for most Toll-like receptors (TLRs) and interleukin-1
receptors (IL-1Rs). MyD88 deficiency in mice leads to susceptibility to a broad range of …

The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response

…, J Yagüe, E Ruiz-Ortiz, J Antón… - Nature …, 2014 - nature.com
Assembly of the NLRP3 inflammasome activates caspase-1 and mediates the processing
and release of the leaderless cytokine IL-1β and thereby serves a central role in the …

[PDF][PDF] Enfermedad de Kawasaki

J Sánchez-Manubens, R Bou, F Prada, J Antón - Protoc diagn ter pediatr, 2020 - aeped.es
La enfermedad de Kawasaki (EK) es una vasculitis sistémica, aguda y autolimitada, con
complicaciones potencialmente peligrosas, que afecta principalmente a lactantes y niños …

Classification criteria for autoinflammatory recurrent fevers

…, F Vanoni, F Bovis, I Aksentijevich, J Anton… - Annals of the …, 2019 - ard.bmj.com
Background Different diagnostic and classification criteria are available for hereditary
recurrent fevers (HRF)—familial Mediterranean fever (FMF), tumour necrosis factor receptor-…

Treating juvenile idiopathic arthritis to target: recommendations of an international task force

…, JD Akikusa, SM Al-Mayouf, J Antón… - Annals of the …, 2018 - ard.bmj.com
Recent therapeutic advances in juvenile idiopathic arthritis (JIA) have made remission an
achievable goal for most patients. Reaching this target leads to improved outcomes. The …

Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial

N Bishop, S Adami, SF Ahmed, J Antón, P Arundel… - The Lancet, 2013 - thelancet.com
Background Children with osteogenesis imperfecta are often treated with intravenous
bisphosphonates. We aimed to assess the safety and efficacy of risedronate, an orally …

Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative

T Constantin, I Foeldvari, J Anton, J De Boer… - Annals of the …, 2018 - ard.bmj.com
Background In 2012, a European initiative called Single Hub and Access point for pediatric
Rheumatology in Europe (SHARE) was launched to optimise and disseminate diagnostic …

Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis

…, E Rabinovich, M Riebschleger, J Antón… - Arthritis care & …, 2013 - Wiley Online Library
Objective Systemic juvenile idiopathic arthritis (JIA) is characterized by fevers, rash, and
arthritis, for which interleukin‐1 (IL‐1) and IL‐6 inhibitors appear to be effective treatments. …

Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus

…, R Merino, J Peralta, MJ Rúa, P Tejada, J Antón - Rheumatology …, 2015 - Springer
Uveitis associated with juvenile idiopathic arthritis (JIA) typically involves the anterior
chamber segment, follows an indolent chronic course, and presents a high rate of uveitic …